A Study on the Role of Heart Type Fatty Acid Binding Protein in Acute Myocardial Infarction by Shama Prakash, K
A STUDY ON THE ROLE OF HEART TYPE FATTY  
ACID BINDING PROTEIN IN ACUTE 
MYOCARDIAL INFARCTION 
 
 
submitted to 
The Tamil Nadu Dr.M.G.R.Medical University  
 
M.D. DEGREE EXAMINATION 
BRANCH – I (GENERAL MEDICINE) 
 
 
 
 
 
 
 
 
 
 
KILPAUK MEDICAL COLLEGE 
 
THE TAMIL NADU DR.M.G.R. MEDICAL UNIVERSITY 
CHENNAI 
 
                                                  APRIL 2011 
 
 
BONAFIDE CERTIFICATE 
 
 This is to certify that "A STUDY ON THE ROLE OF HEART 
TYPE FATTY ACID BINDING PROTEIN IN ACUTE MYOCARDIAL 
INFARCTION " is  a  bonafide work done by Dr. Shama Prakash.K, post 
graduate student, Department of General Medicine, Kilpauk Medical College, 
Chennai-10, under my guidance and supervision in partial fulfillment of 
regulations of The Tamilnadu Dr.M.G.R.Medical University for the award 
of M.D.Degree Branch I (General Medicine) during the academic period 
from May 2008 to April 2011. 
 
 
Dr. V.Kanagasabai, M.D., 
  Dean 
Kilpauk Medical College, 
Chennai – 10 
 
 
 
 
 
Prof.G.Rajendran, M.D., 
Professor and Head, 
Department of Internal Medicine, 
Kilpauk Medical College, 
Chennai-10. 
Prof. N.Raghu,  M.D., 
Professor, 
Department of Internal Medicine, 
Kilpauk Medical College, 
Chennai – 10.  
 
1 
 
INTRODUCTION 
Coronary heart disease which was earlier more common in developed 
countries is now common in developing countries including India.1 Asian 
Indians have much higher incidence of coronary artery disease (CAD) as 
compared to all other ethnic groups.CAD among Asian Indians has been 
found to be more severe, diffuse and associated with serious complications 
and increasing mortality at a younger age and its incidence has dramatically 
increased in recent years.2 
Acute myocardial infarction (AMI) is the rapid development of 
myocardial necrosis caused by a critical imbalance between oxygen supply 
and demand of the myocardium. Studies have shown that effective salvage 
of the ischaemic myocardium following a sudden or ongoing interruption of 
coronary blood flow requires immediate initiation of therapy.3Diagnosis in 
the early stages of AMI is sometimes difficult because the initial ECG may 
not reveal any changes indicative of myocardial ischaemia 4 and also due to 
the delayed release of serum cardiac biomarkers such as CK-MB and 
Troponins. Hence detection of a rapidly appearing serum biomarker for 
myocardial damage would facilitate a more appropriate diagnostic and 
therapeutic approach in patients with chest pain who are suspected to have 
AMI. Although myoglobin is considered as an useful marker for early 
diagnosis of AMI 5 it has been reported to be less specific.6  
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Heart type fatty acid binding protein (H-FABP) has been proposed as 
an early cardiac biomarker for the diagnosis of AMI using animal       
models 7,8,9 and clinical samples.10,11,12,13H-FABP is able to detect 
myocardial damage as soon as one hour after the onset of ischaemia and 
therefore is regarded as the earliest plasma biomarker available to diagnose 
AMI.14 A bedside test for H-FABP providing results within 15 minutes is 
available and it can reduce the diagnostic uncertainty in those suspected to 
have AMI who present in early hours.15  But not much data is available 
regarding the utility of H-FABP in Indian population. 
Hence in this study the role of Heart type fatty acid binding protein in 
the diagnosis of acute myocardial infarction, particularly in the initial hours 
after symptom onset, is studied and compared with the established 
biomarkers CK-MB and Troponin. 
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                                AIM  OF  THE  STUDY 
1. To study the role of heart type fatty acid binding protein in the  
diagnosis of acute myocardial infarction. 
2. To compare the heart type fatty acid binding protein with the standard 
cardiac biomarkers  CK-MB and Troponin. 
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                            REVIEW OF LITERATURE 
HISTORICAL REVIEW: 
William Harvey proposed that blood circulates because of the force of 
the heart (1616).16,17 On July 21, 1768, William Heberden presented "Some 
Account of a Disorder of the Breast" to the Royal College of Physicians, 
London: "But there is a disorder of the breast marked with strong and 
peculiar symptoms, considerable for the kind of danger belonging to it, and 
not extremely rare. The seat of it, and sense of strangling and anxiety with 
which it is attended, may make it not improperly be called angina 
pectoris."16,18 His classic account marks the beginning of our appreciation of 
coronary artery disease. Edward Jenner and Caleb Parry were the first to 
suspect a coronary oetiology, which Parry published in 1799. Nevertheless, 
a coronary cause of angina pectoris was not readily accepted until the late 
19th century.19 Karl Huber  suggested that atheroma could cut off the blood 
supply and lead to myocardial fibrosis (1882).18 Adam Hammer was the first 
to report the premortem diagnosis of myocardial infarction (1878). 
By the late 19th century, angina pectoris was linked with coronary 
artery disease, although there was confusion between angina pectoris and 
myocardial infarction. Coronary disease was thought to be uncommon at 
that time.  In 1901, Osler called the anterior branch the "artery of sudden 
death" later stating that "the tragedies of life are largely arterial." The 
concept that coronary thrombosis was always fatal was finally dispelled by 
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James Herrick (1912).20,21  Herrick was the first to grasp the variable course 
of myocardial infarction. The three-lead electrocardiogram was used by 
Herrick and Smith to diagnose experimental infarction (1918) and in 
humans by Pardee (1920).22 Precordial leads, introduced by Frank Wilson in 
the 1930s, furthered the diagnosis. By the 1930s, myocardial infarction was 
a familiar diagnosis felt to be increasing in frequency. The clinical-
pathologic correlations of atherosclerosis and thrombosis with infarction 
were greatly strengthened by the 1940 postmortem coronary injection 
studies of Blumgart, Schlesinger, and Davis. Autoradiographic postmortem 
studies by Fulton in Glasgow (1976) and DeWood's coronary arteriographic 
studies (1980) finally proved that a thrombus was the primary event. The 
"vulnerable plaque" hypothesis (1966) has gained widespread support as the 
cause of acute coronary disease and sudden death. Inflammation, ignited by 
risk factors underlies "atherothrombosis," and plaque disruption is now 
realized to be multifocal.23    
EPIDEMIOLOGY: 
          The 20th century saw unparalleled increase in life expectancy and 
major shift in the causes of illness and death throughout the world.24 During 
this transition , cardiovascular diseases (CVD) became the most common 
cause of death worldwide. A century ago CVD accounted for less than 10 
percent of all deaths. Today it accounts for approximately 30 percent of 
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deaths worldwide including nearly 40 percent in high income countries and 
about 28 percent in low and middle income countries.25 . 
             One sixth of the world’s population lives in India and India is 
experiencing an alarming increase in heart disease.CVD accounted for 32% 
of all the deaths in 2000 26and the WHO estimates that 60% of the world’s 
cardiac patients will be Indians by 2010. As expected, CVD mortality rates 
tend to be higher in urban than the rural areas and  CVD is much more 
prevalent among the upper and middle classes.27,28 CAD appears to be 
dominant form of CVD in India. From the 1960’s to the 1990’s the CAD 
prevalence increased two fold in rural India and three-fold in urban India. 
The prevalence is even higher in South India.29   
ANATOMY OF CORONARY CIRCULATION30 
Blood supply to the heart comes from the right and left coronary arteries. 
Right Coronary Artery (RCA) 
It arises from right aortic sinus and descends in the right 
atrioventricular groove curving posteriorly at the right cardiac border to 
reach the crux. 
The branches of right coronary artery are, 
A. Conus artery is the first branch of RCA, arising within few 
millimeters of origin of RCA. It passes anteriorly and upwards over 
the RV outflow tract towards left anterior descending artery. 
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B. Sino atrial node artery is second branch of RCA. In about 38% of 
patients, it may arise from left circumflex artery. It sends branches to 
sinus node and usually also to right atrium or both atrium. 
C. Acute marginal branches arise from mid portion of RCA. There are 
one or more medium sized branches which supply anterior wall of 
RV. 
D. Posterior descending artery is the next important branch of RCA. 
When RCA is dominant (in 85% of the patients), the posterior 
descending artery originates at or shortly before the crux and passes 
forward in the posterior interventricular groove, giving rise to number 
of small inferior septal branches, which supply the lower portion of 
interventricular septum.After giving rise to posterior descending 
artery, dominant RCA continues beyond the crux and passes upwards 
in the distal portion of left atrioventricular groove, where it gives rise 
to posterior left ventricular branches. 15% of patients do not have 
RCA dominance. About half of these patients have left circumflex 
artery dominance. Other half of patients without RCA dominance 
have balanced circulation - RCA gives rise to posterior descending 
artery and left circumflex artery gives rise to posterior left ventricular 
branches. 
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Left Coronary Artery 
Left main coronary artery arises from the upper  portion of the left 
aortic sinus. It passes behind the right ventricular outflow tract, extending 
for      0-10 mm and then bifurcates into left anterior descending artery and 
left circumflex artery. 
A. Left anterior descending artery (LAD) passes down the anterior inter- 
ventricular groove towards the cardiac apex. Its major branches are 
septal and diagonal branches. Septal branches arise from left anterior 
descending at approximately  90 degree angle and pass into 
interventricular septum. Diagonal branches pass over the anterolateral 
aspect of the heart. 
B. Left circumflex artery (LCA) originates at the bifurcation of left main 
coronary artery and passes down the left atrioventricular groove. The 
left circumflex artery usually gives off one to three obtuse marginal 
branches as it passes down the atrioventricular groove. These are the 
principal branches of the left circumflex artery , since they supply the 
free wall of the left ventricle along its lateral aspect.Beyond the origin 
of obtuse marginal branches, the distal left circumflex artery tends to 
be small. The left circumflex artery also gives rise to 1 or 2  left atrial 
circumflex branches, which supply the lateral and posterior aspects of 
the left atrium.  
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Coronary Venous System 
Coronary veins return blood from the myocardial capillaries to the 
RA. 
A. The great cardiac vein lies in the anterior interventricular sulcus, it 
drains the base of the heart and drains into the coronary sinus. It 
receives tributaries from the anterior interventricular septum, the wall 
of the both ventricles and the left atrium. 
B. The middle cardiac vein drains into the coronary sinus and receives 
tributaries from the posterior interventricular septum and ventricular 
walls. 
C.  3-12 anterior cardiac veins drain the wall of the right ventricle and 
empties  directly into the right atrium. 
D. The coronary sinus is formed as a continuation of the great cardiac 
vein,  is  2-5 cm long, it receives veins from the posterior left 
ventricle and the left  atrium. It drains directly into the right atrium. 
RISK FACTORS FOR CORONARY ARTERY DISEASE 31 
1. Established Evidence 
Advanced Age, Physical inactivity, Obesity, Smoking32,33,34,  
Hypertension34, Diabetes Mellitus 35,36, Increased LDLc 34and   
Decreased HDLc.  
2. Emerging Risk Factors 
a) Inflammatory markers: CRP , Serum Amyloid A. 
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b) Procoagulant markers: Homocysteine 37 , Plasminogen activator    
inhibitor type 1 (PAI) 38,  Lipoprotein (a). 38 
c) Process markers: Fibrinogen 39, D dimer ,Coronary artery 
calcification.  
d) Genetic factors: Tumor necrosis factors , Transforming growth 
factors ,  IL-1 , CD 14 , Adhesion molecules etc. 
RISK FACTORS FOR ASIAN INDIANS 29 
A. Non modifiable: Male age > 35 years, Female age > 45 years, Family       
history of premature CAD (at age <55 years). 
B. Modifiable –Non lipids: Hypertension, Smoking / tobacco abuse,  
Diabetes mellitus / insulin resistance syndrome,  Obesity / BMI > 22, 
Homocysteine > 10 micro mol/L, High PAI – 1. 
C. Modifiable-Lipids:Total Cholesterol >150 mg%,                      
Triglycerides > 150mg%, LDLc > 100 mg%, Apo (A) < 100 mg%,    
 HDLc Males < 40 mg% , HDLc Females < 50 mg%, TC/HDLc > 
4.5,  LDLc/HDLc > 3.5, Apo (A)/Apo (B) < 1.2,                                         
Lipid Tetrad= LP(a)*TG*LDLc%HDLc  > 20,000 
ACUTE MYOCARDIAL INFARCTION: 
The WHO criteria for the diagnosis of AMI includes:  
1. History of ischaemic type of chest discomfort.  
2. Evolutionary changes on serially obtained ECG tracings.  
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3. Typical rise and fall in serum cardiac markers.  
Diagnosis of AMI requires at least two of the three criteria.
40 
But  
recently myocardial infarction has been redefined. 
REVISED DEFINITION OF MI 41 
Criteria for acute, evolving or recent MI 
Either one of the following criteria satisfies the diagnosis for an acute, 
evolving or recent MI: 
(1) Typical rise and/or  fall of biochemical markers of myocardial  
          necrosis with at least one of the following: 
a) Ischaemic symptoms. 
b) Development of pathologic Q waves in the ECG. 
c) ECG changes indicative of ischaemia (ST elevation or depression). 
d) Imaging evidence of new loss of viable myocardium or new regional  
      wall motion abnormality. 
(2) Pathological findings of an acute MI. 
Criteria for Healing or Healed MI 
Any one of the following criteria satisfies the diagnosis for healing or  
healed  MI: 
1) Development of new pathologic Q waves on serial ECGs. The  
patient may or may not remember previous symptoms. Biochemical 
markers of myocardial necrosis may have normalized, depending on 
the length of time that has passed since the infarction developed. 
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2) Pathological findings of a healed or healing infarction. 
Hence in the diagnosis of Acute MI the role of cardiac biomarkers has 
gained more significance. 
CAUSES OF AMI  
Almost all MIs result from coronary atherosclerosis, generally with  
superimposed coronary thrombosis.  
CAUSES OF MI WITHOUT CORONARY ATHEROSCLEROSIS 42 
Coronary artery disease other than atherosclerosis 
Arteritis 
Leutic, Granulomatous (Takayasu disease), Polyarteritis nodosa, 
Mucocutaneous lymph node (Kawasaki) syndrome,  Disseminated lupus 
erythematosus, Rheumatoid arthritis,  Ankylosing spondylitis. 
Trauma to coronary arteries 
Laceration, Thrombosis, Iatrogenic, Radiation etc. 
Coronary mural thickening with metabolic disease or Intimal 
Proliferative disease 
Mucopolysaccharidoses (Hurler disease), Homocysteinuria, Fabry’s  
disease, Amyloidosis, Juvenile intimal sclerosis (idiopathic arterial  
calcification of infancy), Intimal hyperplasia associated with contraceptive 
steroids or with the postpartum period, Pseudoxanthoma elasticum, 
Coronary fibrosis caused by radiation therapy. 
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Luminal narrowing by other mechanisms 
Spasm of Coronary arteries (Prinzmetal angina with normal Coronary 
arteries), Spasm after nitroglycerin withdrawal, Dissection of the aorta, 
Dissection of the Coronary artery. 
Emboli to Coronary arteries 
Infective endocarditis, Nonbacterial thrombotic endocarditis, Prolapse 
of  the mitral valve, Mural thrombus from LA, LV or pulmonary veins,  
Prosthetic valve emboli, Cardiac myxoma, Emboli associated with  
cardiopulmonary bypass surgery and coronary arteriography, Paradoxical  
emboli, Papillary fibroelastoma of the aortic valve (“fixed embolus”),  
Thrombi from intracardiac catheters or guidewires. 
Congenital coronary artery anomalies 
Anomalous origin of left coronary from pulmonary artery, Left 
coronary  artery from anterior sinus of valsalva, Coronary artery aneurysms, 
Coronary arteriovenous and arteriocameral fistulas. 
Myocardial oxygen demand-supply disproportion 
Aortic stenosis, Incomplete differentiation of the aortic valve, Aortic  
insufficiency, Carbon monoxide poisoning, Thyrotoxicosis, Takotsubo  
cardiomyopathy, Prolonged hypotension. 
Hematological (in situ thrombosis) 
Polycythaemia Vera, Thrombocytosis, Disseminated intravascular  
coagulation, Hypercoagulability etc. 
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Miscellaneous 
Cocaine abuse, Myocardial contusion, Myocardial infarction with 
normal  coronary arteries, Complication of cardiac catheterization. 
PATHOLOGY AND PATHOPHYSIOLOGY OF MI 43,44 
Almost all myocardial infarctions result from coronary 
atherosclerosis,  generally with superimposed coronary thrombus. During 
natural evolution of atherosclerotic plaque, an abrupt and catastrophic 
transition may occur, characterised by plaque rupture and exposure of 
substance that promotes platelet activation and thrombin generation. The 
resultant thrombus interrupts the blood flow to cause myocardial infarction. 
The plaques which are more likely to rupture are one with thick lipid core 
and thin fibrous cap. The process of plaque rupture is likely to be 
multifactorial.  Stress induced by intraluminal pressure, coronary vasomotor 
tone and disruption of nutrient vessels combine to produce plaque rupture at 
margins of fibrous cap. Such rupture leads to sudden occlusion of the vessel 
due to aggregation of RBCs, Platelets, macrophages  and leads subsequently 
to thrombus formation. There is further vasoconstriction due to 
Thromboxane A2, a powerful  vasoconstrictor liberated from the platelets.  
If due to natural fibrinolytic  substances in the body a partial or complete 
lysis of the clot occurs, the  patient develops unstable angina or non Q wave 
MI or NSTEMI due to  partial restoration of blood flow. However if no such 
fibrinolytic activity occurs, the patient develops STEMI or Q wave MI.  
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Left Ventricular Systolic Function 
Upon interruption of flow the affected myocardium loses its ability to  
shorten and perform contractile work. Four abnormal contraction patterns  
are seen in sequence as follows, 
1) Dys-synchrony: Dissociation in the time course of contraction of     
adjacent segments. 
2) Hypokinesis: Reduction in extent of shortening. 
3) Akinesis:  Cessation of shortening. 
4) Dyskinesis: Paradoxical expansion.45,46 
Initially, the non-infarcted area shows hyperkinesia. This is thought to 
be  due to compensatory mechanisms and subsides by about 2 weeks after  
infarction. If sufficient quantity of myocardium is affected, LV pump  
function becomes depressed - cardiac output, stroke volume and blood  
pressure decreases and the end systolic volume increases. In fact, the  
degree to which the end systolic volume increases is the most powerful  
indicator of mortality of acute myocardial infarction. When 15% of LV is  
involved, ejection fraction may be depressed.Clinical heart failure occurs  
when thearea of abnormal contraction exceeds 25%, whereas cardiogenic  
shock occurs with loss of 40% of LV myocardium. 
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Left Ventricular diastolic function 
Left ventricular diastolic properties are altered in infarcted and 
ischaemic myocardium, leading initially to an increase but later to a 
reduction in left  ventricular compliance. The magnitude of the diastolic 
abnormality appears to be related to the size of the infarct. 
Ventricular remodelling 
As a consequence of MI, changes occur in the LV size, shape and  
thickness involving both the infarcted and non-infarcted segments and are  
collectively referred to as ventricular remodelling , a process that  in turn 
can influence ventricular function and prognosis of the patient .47  Infarct  
expansion plays an important role in ventricular remodelling.Remodelling  
is also caused by dilatation of viable portion of ventricles, commencing  
immediately and progressing for months or years thereafter.48 
CLINICAL MANIFESTATIONS OF AMI  
Precipitating factors:  
1) Unusually heavy exercise in fatigued or emotionally stressed or  
habitually inactive patients. 49 
2) Non cardiac surgical procedure. 
3) Hypotension and increased myocardial oxygen demands secondary  
to aortic stenosis, fever, tachycardia and agitation. 
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4) Other less common factors includes respiratory infection, hypoxaemia 
of any cause, pulmonary embolism, hypoglycaemia, administration of 
ergot preparation, use of Cocaine, sympathomimetics, allergy etc. 
Circadian Periodicity 
Peak incidence of myocardial infarction is between 6 A.M. and 12 
noon. Early morning hours are associated with rise in plasma 
catecholamines  and cortisol and increase in platelet aggregability. 
Prodromal symptoms 
Usually characterized by malaise, exhaustion and chest  discomfort.  
Nature of pain  
It is variable in intensity. In most patients it is severe and in some 
instances it is intolerable. The pain is prolonged often lasting for more than 
30 minutes and frequently for hours. The discomfort is described as 
constricting, crushing or compressing, often the patients complain of 
sensation of a heavy weight or squeezing in the chest, sometimes it may be 
characterized as stabbing. The pain is usually retrosternal in location, 
spreading frequently to both the sides of anterior chest. Often pain radiates 
down the ulnar aspect of left arm, producing tingling sensation in the left 
wrist, hand and finger. In some patients, pain of AMI, may begin in the 
epigastrium and simulate a variety of acute abdominal disorders. In other 
patients discomfort of AMI radiates to shoulder, upper extremities, neck, 
jaw and interscapular region. In some patients, particularly elderly, it is 
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manifested clinically not by chest pain but rather by symptoms of acute 
LVF, chest tightness, extreme weakness and fatigue or frank syncope
50
. Pain 
of myocardial infarction represents ongoing ischaemia.  
Other Symptoms 
Nausea and vomiting may occur. These symptoms occur more 
commonly in patients with inferior wall MI. Occasionally, patients complain 
of diarrhoea or a violent urge to evacuate the bowels during the acute 
phase.Other symptoms include feeling of profound weakness, dizziness, 
palpitations, cold perspiration  and sense of impending doom. 
Atypical presentations  
These include heart failure, atypical location of pain, CNS 
manifestations  resembling those of stroke ,apprehension and nervousness, 
sudden mania or psychosis, syncope, overwhelming weakness, acute 
indigestion and peripheral embolization. Silent MI is common in diabetics, 
hypertensives, women and elderly patients. 
PHYSICAL EXAMINATION 
Patients with AMI often appear anxious and in considerable distress. 
In patient with LVF and sympathetic stimulation, cold perspiration and skin 
pallor may be evident. In patients with cardiogenic shock the skin is cold 
and clammy with cyanosis and marked facial pallor.  
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Heart rate, Blood pressure and JVP 
Heart rate may vary from bradycardia to a rapid or irregular 
tachycardia.Ventricular premature beats are common. Majority of the 
patients are normotensives. Slight hypertensive response is seen in first few 
hours secondary to sympathetic response to pain. Patients with cardiogenic 
shock have systolic BP< 90mmHg and evidence of end organ 
hypoperfusion. More than half of the patients with inferior wall MI have 
excessive parasympathetic stimulation with hypotension, bradycardia or 
both. About half of the patients with anterior wall MI showing sympathetic 
stimulation have hypertension, tachycardia or both
51
. Usually the JVP fails 
to show any abnormality in AMI. But associated right ventricular infarction 
often results in raised JVP. 
Cardiac examination  
Despite severe symptoms and extensive myocardial damage, the 
findings on examination may be unremarkable. In the presence of LV 
systolic dysfunction, an outward movement of LV may be palpated and 
early diastole coincides with S3. On auscultation the S1 is muffled or 
inaudible immediately after MI and the intensity increases during 
convalescence. Soft S
1 
may also indicate prolonged PR intervals. In the 
presence of LBBB, there will be paradoxical splitting of S2. S3 is usually 
heard in patients with large infarction, common in transmural anterior wall 
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than in inferior wall or non transmural MI. An S
4 
is almost universally heard 
in patients with acute MI in sinus rhythm. Systolic murmur, transient or 
persistent can be heard due to papillary muscle dysfunction or LV dilatation 
or tricuspid regurgitation. Moist rales are audible in patients who develop 
LVF or reduction in LV compliance in AMI. In 1967, Killip and Kimball 
proposed a prognostic classification based on presence and severity of 
rales
52
.  
Class I - Free from rales and S
3
 
Class II - Rales in <50% of lung fields with or without S
3
 
Class III - Rales >50% of lung fields with S
3 
.Frequently have pulmonary 
oedema.  
Class IV - Cardiogenic shock with systolic pressure < 90 mm Hg and 
evidence of peripheral vasoconstriction, cyanosis, mental confusion, 
oliguria.  
Mortality rate in these classes were as follows:  Class I - 0 to 5 % , 
Class II- 10 to 15 %, Class III - 35 to 45 % and Class IV - 85 to 95 % . 
 
DIAGNOSIS OF AMI 
It is based on ECG, Cardiac biomarkers and Imaging. The revised definition 
has given greater importance to biomarkers. 
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Cardiac Biomarkers  
Necrosis compromises the integrity of the sarcolemmal membrane  
and intracellular macromolecules (serum cardiac biomarkers) begin to 
diffuse into the cardiac interstitium and ultimately into the microvasculature 
and lymphatics in the region of the infarct .53 The rate of appearance of 
these macromolecules in the peripheral circulation depends upon several 
factors including intracellular location, molecular weight, local blood and 
lymphatic flow and the rate of elimination from the blood.  
 Characteristics of an ideal biomarker are: 
1. For optimal specificity it should be present in high concentration in 
the myocardium and be absent in non myocardial tissue and serum. 
2. For optimal sensitivity it should be rapidly released into the blood 
after myocardial injury (which is based on the molecular size and the 
intracellular location of the molecule) and there should be 
stoichiometric relationship between the plasma level of the marker 
and extent of myocardial injury. 
3. The marker should persist for an appropriate length of time to provide 
a convenient time window. 
4. The assay methodology should be inexpensive and easy to perform.  
No single biomarker satisfying the ideal criteria exists. Wu et al 54 
recommended that two biochemical markers should be used for routine AMI 
diagnosis; an early marker (reliably increased in the blood within 6 hours of 
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onset of symptoms) and a definitive marker (increased in the blood after 6 to 
9 hours and remaining abnormal for several days) 
CONVENTIONAL BIOMARKERS 
ASPARTATE AMINOTRANSFERASE (AST/SGOT)                            
The levels of serum AST begin to rise 3-8 hours after the onset of the 
myocardial injury with peak levels on an average at 24 hours and finally it 
returns to normal levels in 3-6 days. Initially it was considered as a very 
good marker of cardiac injury but later on, its use became limited due to its 
elevation in trauma to skeletal muscles and liver diseases. 55  
LACTATE DEHYDROGENASE (LDH)  
An increase in serum LDH activity is found following myocardial 
infarction beginning within 6 - 12 hours and reaching a maximum at about 
48 hours. It remains elevated for 4 -14 days before coming down to normal 
levels. The prolonged elevation makes it a good marker for those patients 
admitted to the hospital several days after MI. RBC’s are rich in LDH and 
hence, haemolysis may give falsely elevated results. Its use is discouraged 
due to its non-specificity as increased levels are found in progressive 
muscular dystrophy, myoglobinuria, leukaemia, pernicious anaemia, 
megaloblastic and haemolytic diseases 56. 
MYOGLOBIN                                                                                                    
            Myoglobin is a haem protein that is present in the cytoplasm of 
cardiac and skeletal muscle cells; its function is to transport intracellular 
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oxygen. It is elevated in 2 - 3 hours after myocardial injury. The advantage 
of this marker is the high negative predictive value of serum myoglobin for 
excluding early infarction. This has encouraged its use along with more 
specific markers such as CK-MB and cardiac troponins to improve the 
diagnosis of AMI. The disadvantage is that, myoglobin is found both in 
skeletal and cardiac muscles, so its specificity is compromised in the 
presence of skeletal muscle damage 57. 
CREATININE KINASE (CK)AND ITS ISOENZYME MB (CK-MB) 
Serum CK activity increases following MI beginning within 6 hours 
and peaking on an average at 24 hours and returning to normal within 2-3 
days. However, its presence in large amounts in skeletal muscle and 
increased levels found in muscular dystrophy , hypothyroidism , 
hypothermia , alcoholism , cerebrovascular accidents  and  a variety of 
myopathies 58 makes it unsuitable as a marker of myocardial injury. 
                 CK has three isoenzymes namely CK-BB, CK-MB and CK-MM. 
Myocardium contains 40% CK-MB and 60% CK-MM along with traces of 
mitochondrial CK (macro CK type II) whereas skeletal muscles contain 
about 97% CK-MM, 2-3% CK-MB and traces of CK-BB and mitochondrial 
macro type II. Being highest in proportion in the myocardium CK-MB has 
been used as a biochemical marker in patients with suspected AMI. Serum 
CK-MB kinetics gives useful information regarding the extent and timing of 
myocardial injury. It begins to increase between 3-5 hours after the onset of 
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infarction and peaking at 16-20 hours. It has been considered as the ‘Gold 
Standard’ for confirmation of AMI 59. However, the techniques used  
(electrophoresis and immunoinhibition) to quantitate CK-MB catalytic 
activity were not sensitive enough for early use, being relatively non-
specific and long turn-around time restricted its use  primarily for 
confirming MI at 24 hours post injury 60. The CK-MB mass assay has a 
diagnostic sensitivity of 50% at 3 hours. and 80% at 6 hours. It has been 
found that CK-MB mass slope calculated from serial blood samples 
collected 0-12 hours after the onset is a rapid and accurate diagnostic 
approach to categorize the patients with suspected AMI 61. Despite all these 
advantages of     CK-MB mass assay, it has two main limitations: (1) it is 
not perfectly specific to cardiac injury, with increases occurring also during 
massive musculoskeletal injury and (2) the early release pattern limits its 
use for the late MI diagnosis. But it has a definite place for the diagnosis of 
reinfarction  and has prognostic value in patients with unstable angina. The 
ratio of the CK-MB / total CK(>2.5) has also been proposed for the 
diagnosis of MI by some authors 62 but it has been discouraged by others 
due to certain limitations 63 as in following instances: (1) when high levels 
of total CK are present because of skeletal muscle injury (a large quantity of 
CK-MB must be released from the myocardium to satisfy criteria); (2) when 
chronic skeletal muscle injury releases large amounts of CK-MB; and (3) 
when total CK measurements are within the normal reference range for the 
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laboratory and CK-MB is elevated (possibly indicating that a 
microinfarction has occurred). Patients with minimally elevated CK-MB 
and normal CK have a prognosis that is generally worse than that for 
patients with suspected MI but no CK-MB elevation.CK-MB isoforms 
(subtypes) are also considered as sensitive markers for early diagnosis of MI 
. There is only one CK-MB isoform within tissue but after release into the 
circulation CK-MB is chemically modified resulting in two bands on 
traditional high voltage electrophoresis : one tissue subtype MB2 and the 
other the modified subtype MB1. The ratio of MB1/MB2 provides the basis 
for a positive MB subtype result. However, CK-MB isoforms offer no 
advantage over CK-MB mass as an early marker of MI 64 and CK-MB mass 
measurement is more practical to perform in the laboratory and easily 
automated than the measurement of CK-MB isoforms with available 
methods. 
CARDIAC TROPONINS 
These are regulatory proteins found in the skeletal and cardiac 
muscles. The 3 subunits that have been identified include cardiac troponin I 
(cTnI), cardiac troponin T (cTnT) and cardiac troponin C (cTnC)65. The 
complex regulates the calcium-modulated interaction between actin and 
myosin on the thin filament. Each troponin subunit is encoded by a separate 
gene, whereas TnI and TnT exist as specific skeletal and cardiac muscle 
isoforms. The function of cTnI is to inhibit actinomyosin ATPase activity. 
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The cTnC interacts tightly with cTnI, reversing the inhibitory effect. Most 
intracellular cTnI and cTnT is bound to the myofibrils in the cardiac 
myocyte. However, a small percentage exists in a cytosolic pool57. These 
cardiac troponins  appear in the blood as early as 3 - 4 hours after the acute 
episode and remain elevated for 4 - 14 days 66.  The maximal amount of free 
cTnI was released shortly after the injury due to breakdown of the 
myofibrillary complex in damaged myocytes;  cytosolic troponins reach the 
blood stream quickly resulting in a rapid peak of serum troponin which is 
observed during the first few hours 67. This is followed by the release of 
structurally bound troponin resulting in a second peak lasting for several 
days. An increase in the concentration of serum cardiac troponins reflects 
myocardial damage but does not indicate mechanism 65. Both cTnT and 
cTnI are almost equally good markers and it is difficult to say which is 
better because both have some positive and negative points.  cTnI is 100% 
cardiospecific and as opposed to cTnT it is not elevated in chronic renal 
disease, trauma and skeletal muscle disease68. The overall diagnostic 
specificity and efficiency of cTnI is better than cTnT and it is proved to be 
the most sensitive marker in detecting myocardial necrosis following 
percutaneous intervention . However, the third generation cTnT assays don’t 
allow the skeletal TnT interference. Both cTns undergo post translational 
modifications such as phosphorylation, oxidation, reduction, proteolysis and 
form complex with other troponins. cTnI is more prone to these 
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modifications and these modifications may prevent some antibodies used in 
the assay system from binding to the molecules and thereby diminishing the 
signal. There are some discrepancies in the standardization of cTnI assays. 
The same sample tested with assays from different manufacturers may give 
several fold difference in the results whereas cTnT assay is manufactured by 
only one manufacturer . The life-time of cTnT in blood (5-14 days) is some 
what more than that of cTnI (4-10 days).The disadvantages of cardiac 
troponins is its elevation in patients with myocarditis and in such conditions 
where cardiac damage might not be expected such as stroke, pulmonary 
embolism, pulmonary hypertension and severe renal dysfunction. 
NEWER BIOMARKERS 
Heart type fatty acid binding protein (H-FABP) 
Brain Natriuretic Peptide (BNP): BNP is synthesized and stored in atrial 
and ventricular myocytes, although plasma BNP originates mainly from the 
left ventricle. The plasma concentration is related to the magnitude of the 
atrial or ventricular overload. The increase in the circulating concentrations 
of BNP was found soon after AMI as shown by Morita et al 69, whereas 
Morrison et al 70 have shown that the increased value of BNP helps in 
differentiating cardiac and pulmonary causes of dyspnoea. Disorders 
associated with right ventricular dysfunction, such as primary pulmonary 
hypertension, and pulmonary embolism are also associated with increased 
plasma BNP concentration. 
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Glycogen Phosphorylase BB: GPBB is in the form of sarcoplasmic 
reticulum glycogenolysis complex. It is released within 2 - 4 h after the 
onset of myocardial damage and returns to the reference range within 1 - 2 
days after MI. The release of GPBB in parallel with myoglobin or heart-type 
fatty acid binding protein indicates irreversible myocardial damage 71. At 
the time of tissue hypoxia glycogen is broken down, GPBB is converted to a 
soluble form and becomes free to move in the cytoplasm. During ischaemic 
conditions, rapid increase in glycogenolysis and simultaneously increase in 
plasma membrane permeability occurs, which favours early release of 
GPBB. Thus GPBB serves as an accurate marker for the detection of 
ischaemic myocardial damage but is yet to be confirmed with high-quality 
GPBB assays. 
Adiponectin: Adiponectin  is a 247 amino-acid peptide hormone, which 
circulates at a relatively high concentrations in the blood stream, accounting 
for 0.05% of total serum proteins and is inversely associated with obesity, 
insulin resistance, type 2 diabetes mellitus and cardio- vascular diseases 
(CVD)72. 
Xanthine Oxidase: Xanthine oxidase produces oxygen free radicals which 
oxidize cellular  proteins and membranes resulting in myocardial cellular 
injury 73. The elevated levels of xanthine oxidase activity in the blood of 
patients with  myocardial infarction is the main advantage of this marker. 
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But the disadvantage of this marker is that it is also found elevated in non-
cardiac conditions like liver disorders74. 
Pregnancy Associated Plasma Protein A (PAPP-A):  Bayes-Genis et al 
showed the presence of PAPP-A in unstable plaques from patients who died 
suddenly of cardiac causes 75. PAPP-A was abundantly expressed in plaque 
cells and extracellular matrix of ruptured unstable plaques, but not in stable 
plaques. Circulating PAPP-A levels were significantly elevated in patients 
with unstable angina or acute myocardial infarction than in patients with 
stable angina. 
Carbonic anhydrase III: The tissue distribution of carbonic anhydrase III 
is limited to skeletal muscles  and its assay is used in combination with that 
of myoglobin. It has been suggested that an increase in the 
myoglobin:carbonic anhydrase III ratio is diagnostic of myocardial injury76. 
Currently available assays for carbonic anhydrase are relatively time 
consuming, limiting the clinical use of the myoglobin:carbonic anhydrase 
III ratio.  
Myosin light chains: A small amount (<1%) of MLC is found in the  
muscle cell as a cytosolic  precursor of myosin synthesis. This unbound  
free fraction is released into the circulation rapidly after myocardial  injury 
and its molecular size enables it to be filtered by the glomerulus.  Assays 
developed so far tend to be for MLC 1, as MLC 2 is very labile.  However, 
MLC 2 has the potential for greater cardiac specificity 77.After  myocardial 
30 
 
injury, MLC 1 appears in the circulation 3–6 h after the onset  of pain, due 
to the release of the unbound cytosolic fraction. Peak values  occur after 
about 4 days, and elevated plasma concentrations persist for  10–14 days, 
reflecting continuing release from infarcted myofilaments.  
Ischaemia modified albumin (IMA): Under normal physiological 
conditions, transition metals bind to the N-terminus of the albumin 
molecule. Ischaemia causes a structural modification to the N‐terminus of 
the protein possibly as a result of exposure to reactive oxygen species. This 
alters the ability of the protein to bind to metals such as cobalt. The 
albumin–cobalt binding test is a rapid spectrophotometric procedure, which 
can be easily automated, to provide a measure of serum IMA 78.  Serum 
IMA can differentiate myocardial ischaemic patients from non‐ischaemic 
individuals, but is a poor discriminator between ischaemic patients with and 
without MI. 
Markers of inflammation 
Atherosclerosis is associated with an inflammatory process, and 
markers of inflammation are being investigated as potential tools for 
cardiovascular risk prediction. Markers of inflammation such as C-reactive 
protein, Interleukins (IL-18,IL-6), Myeloperoxidase, Whole blood Choline, 
CD-154, Urocortin have also been suggested as predictors of cardiovascular 
risk and  studies are ongoing regarding their usefulness.  
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Electrocardiographic findings  
During initial stage of acute phase of MI, total occlusion of the infarct 
artery produces ST segment elevation. Most patients initially presenting 
with ST elevation evolve Q waves on the ECG and are ultimately diagnosed 
as having sustained a Q wave MI. A small proportion may sustain only a 
non Q wave MI. When the obstructing thrombus is not totally occlusive or 
obstruction is transient or if a rich collateral network is present, no ST 
elevation is seen. Such patients are diagnosed as either unstable angina 
(Biomarkers negative) or a non ST elevation MI (Biomarkers positive). 
Among patients presenting with ST segment elevation, if a serum marker is 
detected and no Q wave develops, the diagnosis of non Q wave MI is 
ultimately made. Serial standard 12-lead ECGs remain a potent and 
extremely clinically useful method for the detection and localization of MI. 
IMAGING 
2D Echocardiography, Doppler Echocardiography, Computed 
Tomography, Cardiac Magnetic Resonance and Nuclear Imaging like 
Radionuclide Angiography, Perfusion Imaging, Infarct Avid Scintigraphy, 
Positron Emission Tomography have also been used to evaluate Myocardial 
Infarction79. 
MANAGEMENT OF AMI 
General measures include: Establishing an IV line, Obtaining initial blood 
samples for cardiac enzymes level, complete blood count, electrolytes and 
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lipid profile, Monitoring vital signs and Pulse oxymetry to measure oxygen 
saturation. 
Oxygen therapy: 2-4 litre /min via nasal prongs is indicated in most 
patients with AMI  because mild hypoxaemia is common. In stable patients 
without hypoxaemia it is usually discontinued after six hours. 
Anti Ischaemic Treatment: Nitrates: Given sublingually or buccal spray 
(0.3 – 0.6 mg).If the pain persists after 3 doses given 5 min apart, IV 
Nitroglycerine 5 – 10 micro gram per minute is advised. 
Beta Blockers: Metoprolol 5 mg IV over (1 -2 min) repeated after 5 min for 
total dose of 15mg, followed by 25-50 mg orally 6th hourly or Esmolol 
0.1mg / kg / min IV. 
Control of Pain: Morphine: 2-5mg IV. May be repeated if necessary.   
Oral anti platelet Therapy: Aspirin-Initial dose of 162 – 325 mg non-
coated formulation, followed by 75-160 mg per day.  Clopidogrel- Loading 
dose 300mg, followed by 75 mg per day.  
Anticoagulant Therapy                          
Heparins: (UFH) Bolus 60-70units /kg (Max 5000 units) IV, followed by 
infusion 12-15 units /kg/hour. 
Deltaparin: 120 IU / kg SC, 12th hourly. 
Enoxaparin: 1mg /kg SC 12th hourly. 
In case of STEMI, patients should be considered for reperfusion therapy 
with thrombolytic agents like, 
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a. Tissue plasminogen activator (tPA): 15mg bolus followed by 50 mg IV 
over first 30 min, followed by 35mg over next 60 min. 
b. Streptokinase (SK) 1.5 million units IV over 1 hour. 
c. Tenecteplase (TNK) 0.53 mg / kg over 10 seconds as a bolus. 
d. Reteplase (rPA) given as double bolus regimen. 10 million units bolus 
over 2-3 min, followed by 10 million units bolus 30 minutes later. 
Patients can also be taken for Primary PCI.  
Activity: After bed rest for the first 12 hours, if no complications, sitting  
is  advised within 24 hours, walking within the room by 2-3 days. After 3  
days  patients can increase walking progressively . 
Diet: For first 4 -12 hours nil orally or clear liquids by mouth.  
Afterwards, diet should provide 30 % calories from fat; carbohydrates  
should make up 50 -55 % of total calories. Food should be enriched with 
high potassium, magnesium and fibre  but low in sodium. 
Bowel: A bedside commode rather than a bed pan, a diet rich fibre and 
routine use of stool softeners is adviced. 
Sedation: Diazepam 5mg or lorazepam 1mg or alprazolam 0.5 – 1 mg can 
be given at bedtime. 
Beta Adrenoreceptor Blockers:  Benefits immediately to relieve pain, to  
reduce the infarct size, to improve myocardial oxygen supply, to decrease  
the incidence of serious ventricular arrhythmias. 
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Angiotensin Converting Enzyme Inhibitors: Benefits by reducing the 
ventricular remodelling after MI and by the reduction of the risk of CCF.  
It should be prescribed within 24 hours of MI. Angiotensin receptor  
blockers may be useful in patients with depressed LV function or with  
clinical heart failure who are intolerant to ACE Inhibitors. 
COMPLICATIONS OF AMI 
A. Mechanical Complications: Ventricular septal rupture , Mitral 
regurgitation , Cardiac rupture, Pseudoaneurysm , Ventricular 
aneurysm . 
B. Ischaemic Complications: Infarct extension, Inhospital reinfarction, 
Post infarction angina.  
C. Embolic Complications. 
D. Inflammatory Complications: 
         Early pericarditis,  Late pericarditis (Dressler`s syndrome). 
     E. Cardiogenic Shock  
     F.Arrhythmias:Ventricular premature beats , Accelerated  
       idioventricular     rhythm,  Ventricular tachycardia , Ventricular 
        fibrillation , Supraventricular arrhythmias , Junctional rhythm ,  
        Sinus   bradycardia , Asystole.  
     G. Atrioventricular and Intraventricular Conduction Blocks 
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HEART TYPE FATTY ACID BINDING PROTEIN 
The fatty-acid-binding proteins (FABP) are a family of cytosolic 
proteins that shows a large degree of structural homology. Discovered by 
Ockner in 1972 in studies on the intestinal absorption of fatty acids 80, they 
are called FABPs because they exhibit a high affinity for the non-covalent 
binding of fatty acids. These proteins are widely distributed and are present 
in the fatty acid metabolizing tissues of many mammals. There are several 
types and all have low molecular mass (12–15kDa), but they differ 
markedly in tissue distribution, concentration within the tissue, isoelectric 
point, binding capacity, and binding specificity 81.The FABPs are relatively 
tissue-specific, and are designated by a letter that refers to their tissue of 
origin, e.g. L-FABP, H-FABP, I-FABP, referring to liver, heart and 
intestinal FABPs respectively; tissue-specific FABPs have also been 
reported in the muscle, adipose tissue, kidney, brain and nerve cells. Tissue-
specific FABPs such as L-FABP and I-FABP have been used to detect 
pathologies in these tissues using specific antibodies raised against these 
proteins 82. Different FABPs share between 30–80% amino acid sequence 
homology.   
                  Heart-FABP is a small (15 kDa) soluble non-enzyme protein. It 
is composed of 132 amino acids 83. It is one of the most abundant proteins in 
the heart and comprises 5–15% of the total cytosolic protein pool in the 
aqueous cytoplasm.  The gene is located on chromosome 1 84. H-FABP 
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binds two molecules of fatty acids and is involved with the delivery of fatty 
acyl coenzyme A for oxidation with the generation of energy in the 
mitochondria. Myocardial ischaemia results in a significantly higher level of 
fatty acids in the plasma and the myocardial tissue, which can be harmful to 
the heart 85. The presence of H-FABP may serve a protective function for 
the myocardial cells against the oxidation of these fatty acids while still 
having these substances readily available for the metabolic needs of the cell. 
During ischaemia (e.g. AMI), H-FABP leaks out of myocardial tissue and 
the concentration increases in the plasma 86. The leakage of H-FABP from 
the myocardium may make the myocardium more vulnerable to the harmful 
effects of fatty acids during reperfusion and may account for some of the 
complications seen during reperfusion, e.g. arrhythmias. Some reports have 
suggested another protective role for H-FABP, as scavengers of free radicals 
that are present in the heart during ischaemia 87.  
             The different FABPs from heart, liver and intestine share between 
20–35% amino acid sequences homology and heart, nerve, and adipose 
tissue FABPs share 60–80% amino acid sequence homology. Antibodies 
raised against heart, liver or intestinal FABPs in the earlier studies may thus 
have up to 5% cross-reactivity with each other and have a detection limit of 
around 1ng/ml. The newer assays have a much improved sensitivity and can 
detect H-FABP in concentrations as low as 0.25 ng/ml; the cross-reactivity 
with other tissue FABPs is <0.005% 88.  
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               The rationale for the use of H-FABP as a marker for the early 
diagnosis of myocardial injury is based on the following features: (i) the 
presence of this soluble protein in the myocardium in high concentration (ii) 
virtual confinement to the cytoplasmic space (iii) small molecular size (iv) 
relative tissue specificity, with a relative distribution of H-FABP outside the 
heart similar to that of CK-MB89 and (v) early release into the plasma and 
urine (within 2h) after onset of myocardial injury. H-FABP bears a 
considerable resemblance to myoglobin in terms of size, location within the 
cell, release and clearance kinetics. However, when compared to myoglobin, 
H-FABP concentration in the heart muscle is greater than that in skeletal 
muscles, and its normal baseline concentration is several fold lower than 
that of myoglobin. These advantages make H-FABP  potentially a more 
suitable cardiac marker than myoglobin .90,91,92 
Measurement of H-FABP and normal range 
The method of measurement is based on sandwich ELISA) using two 
monoclonal antibodies specific for H-FABP 93. The normal ranges reported 
for H-FABP in plasma and serum are assay and method dependent. Tanaka 
et al. (1991) has reported the normal range for  H-FABP to be 0.0–2.8μg/l; 
10 Wodzig et al. (1997) reported 0.3–5μg/l as the normal limit; 88 and Tsuji 
et al. (1993) used 3μg/l (normal range  0–0.6μg/l).12 H-FABP is not likely to 
be found in the blood stream under normal conditions.   
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Plasma H-FABP and acute myocardial infarction 
H-FABP was introduced by Glatz in 1988 as a potential novel 
biochemical marker for the early diagnosis of AMI.94 This assumption was 
soon confirmed in several studies.10,11,95 Under normal conditions  H-FABP 
is not present in plasma or interstitial fluid, but is released into the blood 
upon cellular injury. The cytoplasmic to vascular concentration of H-FABP 
is of the order of 200000:1. This makes the plasma estimation of H-FABP 
suitable for the early detection and quantification of myocardial tissue 
injury. The H-FABP is released into the plasma within 2 hours after 
symptom onset and is reported to peak at about 4–6 hours and return to 
normal base line value in 20 hours. Within the period of  30–210 minutes 
after symptom onset, H-FABP has >80% sensitivity for the diagnosis of 
AMI.11 Within the interval of 0–6 hours after symptom onset, the other 
cardiac markers such as creatine kinase, CK-MB mass or activity, cardiac 
cTnI and cTnT will only be starting to accumulate in the plasma and their 
sensitivity has been reported to be around 64%.96 
Urinary H-FABP and acute myocardial infarction 
 H-FABP is eliminated from the circulation by the kidney, but the 
precise mode of renal handling of H-FABP is unknown. A rise in serum and 
urine H-FABP concentration above normal values is seen in patients who 
present with AMI as early as 1.5 hours after the symptom onset. 10Assays 
that measure H-FABP in urine samples were able to accurately diagnose 
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patients with AMI and provide reliable estimation of infarct size9. However, 
the measurement of infarct size based upon urinary H-FABP may be 
influenced by several factors, such as renal blood flow, perfusion pressure, 
glomerular filtration rate, tubular absorption and diseases of the kidney. 
Measurement of urinary and plasma H-FABP in the presence of kidney 
diseases may lead to underestimation and overestimation, respectively, of 
the size of infarct due to impairment of excretion of  H-FABP 97. H-FABP 
circulates for longer (>25 hours) after AMI in the presence of renal failure11. 
Several sensitive assays that can measure H-FABP in urine samples are 
available.10,12  
Limitations of H-FABP assays 
H-FABP is excreted by the kidney and renal insufficiency results in 
decreased clearance of H-FABP, thereby elevating the concentration and 
prolonging the circulation time. In situations of AMI and renal failure, 
measurement of plasma H-FABP could lead to overestimation of 
myocardial infarct size and could interfere with its use for the detection of 
re-infarction 97. However, renal failure is readily detectable in standard 
biochemical analysis and should not confound the diagnostic specificity of 
H-FABP, for the vast majority of patients. The main disadvantage of 
myoglobin or H-FABP as early markers of myocardial injury is lack of 
complete specificity, due to the presence of both in skeletal muscles. Severe 
skeletal muscle injury may result in the release of both proteins in sufficient 
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quantity to interfere with the specificity of the assay. Both proteins are 
released into the plasma after injury at about the same time and in a ratio 
similar to the concentration of the proteins in the tissue of origin, therefore 
the measurement of the myoglobin: H-FABP ratio could be useful for 
discriminating between cardiac and skeletal muscle damage. A 
myoglobin:H-FABP ratio ∼5 is considered to be specific for the heart; a 
ratio ∼21–70 is more indicative of skeletal muscle damage6. The 
combination of the two markers in a ratio has been reported by some 
investigators to increase the diagnostic specificity for the diagnosis of AMI 
more than relying on either marker alone. However, the use of this ratio 
should not be a rigid criterion, as overlaps do occur. Some investigators did 
not find any additional value in myoglobin:H-FABP ratio over the 
measurement of H-FABP alone 6,92.  
H-FABP and acute myocardial infarction after surgery 
H-FABP peaks early and may be useful for the early detection of 
myocardial injury after surgery. The plasma concentration of H-FABP is 
increased relatively early, compared to CK-MB and cTnT, after aortic 
declamping in CABG surgery. The time to peak concentration was 
significantly shorter for plasma H-FABP (1.4 ± 0.5hours) than for  
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CK-MB (2.5±0.5hours) or cTnT (6.6±1.3hours). Similar findings were 
reported in other studies.98 H-FABP was not increased in low-risk patients 
after CABG surgery without cardiopulmonary bypass.99  
H-FABP and detection of reperfusion 
H-FABP has been reported to be a sensitive marker for the detection of 
reperfusion after thrombolytic treatment. Abe et al. (1996) demonstrated 
that a rise of H-FABP ratio of ≥1.5 (compared to pre-treatment 
concentration), 30minutes after thrombolytic treatment, was associated with 
100% accuracy for the detection of reperfusion. This accuracy dropped to 
94% at 60 minutes after thrombolytic treatment.95 The advantage of using 
H-FABP is that reperfusion is ascertained very quickly, in some studies as 
early as 15 minutes. In a study by Ishii et al (1995), the predictive accuracy 
of H-FABP ratio > 1.8 for the detection of reperfusion within 60 minutes of 
initiation of treatment was 93% at 15 minutes, 98% at 30 minutes and 100% 
at 60 minutes after reperfusion.100  
H-FABP and detection of re-infarction 
The features of an ideal marker for early re-infarction are early 
release and clearance from the circulation, thus permitting a prompt return 
to pre-infarction concentrations. H-FABP fulfills these features, appearing 
within 3 hours after infarction, peaking early at about 5 hours and returning 
to baseline concentrations about 20 hours after symptom onset.11 Re-
infarction is shown by a rapid rise in H-FABP concentration in serum 
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compared to the previous value. H-FABP can detect re-infarction when it 
occurs 10 h after symptom onset.6 Other cardiac biomarkers such as  cTnI, 
cTnT and LDH take several days to return to the pre-infarction levels and 
thus are not sufficiently sensitive for the detection of re-infarction.  
 
H-FABP and estimation of infarct size 
Accurate measurement of infarct size is possible using nuclear 
studies, but is not practical for routine use because it is expensive, requires 
high technology and exposes patients to additional radiation. Cardiac 
markers offer an alternative for the estimation of infarct size. The rapid and 
quantitatively robust release of H-FABP into plasma after symptom onset 
and its rapid clearance from the circulation within 24 hours, makes it 
potentially suitable for the early estimation of infarct size, provided that 
blood is sampled sufficiently frequently.97 Sohmiya et al. (1993) showed 
good correlation between myocardial infarct size measured from plasma H-
FABP and infarcted myocardium estimated from triphenyl tetrazolium 
chloride (TTC) staining.9 A study by Glatz et al. (1994) using H-FABP for 
the early estimation of infarct size, showed a good correlation between H-
FABP, CK-MB and α-hydroxybutyrate dehydrogenase (α-HBDH) for the 
estimation of infarct size. The advantage of H-FABP is that this 
measurement is completed much earlier than with the other two markers: 24 
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hours, 48 hours and 72 hours for H-FABP, CK-MB, and  α-HBDH, 
respectively.101  
Excretion of heart type fatty acid binding protein 
It is not clear at present whether H-FABP reaches the circulation 
trans-endothelially or via the lymphatic system or both, after its release from 
the cell into the intercellular space. The rapid appearance in the blood may 
suggest the first route. The route of elimination from the circulation is 
assumed to be the kidney, based on direct and indirect evidences.  
Supporting literatures :  
Some studies are discussed here to enlighten the present study: 
  In a study by Okamoto et al3 to compare the role of H-FABP in AMI 
with that of Myoglobin and CK-MB, the overall sensitivity within 12 hours 
of symptom onset was 92.9% for H-FABP,88.6% for myoglobin and 18.6% 
for CK-MB. The overall specificity was 67.3% for H-FABP, 57.1% for 
myoglobin and 98.0% for CK-MB. The diagnostic efficacy with these 
markers were 86.2%(H-FABP),80.4%(myoglobin) and 39.2%(CK-MB) 
respectively.  
A study by Priya Gururajan et al102 at Chennai showed H-FABP to be 
a good discriminator between patients with and without IHD. It also showed 
that whereas troponin levels rise more than 6 hours after symptom onset, H-
FABP is usually positive within the first 4 hours. 
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A study by Ruzgar et al103 showed sensitivity of 38% with troponin, 
76% with CK-MB and 95% with H-FABP in patients admitted within 6 
hours of symptom onset. 
A study by Seino Y et al 104 showed 89% sensitivity of H-FABP 
within 2 hours of symptom onset compared to 22% with troponin and 38% 
with myoglobin. 
In a study by Mad P et al 105 , in 280 patients presenting to the 
hospital with a median time of  3 hours after symptom onset, H-FABP had a 
sensitivity of 69% and specificity of 74% and AMI was diagnosed 
significantly earlier than by troponin. 
A study by Karthik Viswanathan et al106showed that elevated  
H-FABP is an independent prognostic marker in patients with suspected 
acute coronary syndrome and that it identifies high risk troponin negative 
chest pain patients reliably. 
But a study by Jonathan Rosman et al 107failed to show any advantage 
of H-FABP over troponin.  
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                      MATERIALS AND METHODS 
This study was carried out in the Department of General Medicine 
and Cardiology at Government  Kilpauk  Medical College &  Hospital, 
Chennai –10 during the period between  November  2009 and October 
2010.This study was ethically approved by the Ethical committee of 
Government Kilpauk Medical College and Hospital, Chennai – 10. 
This is a cross sectional study. 50 patients admitted to the Intensive 
Cardiac Care Unit (ICCU) with ischaemic symptoms were enrolled. They 
were categorised in to those coming to the hospital within 4 hours of 
symptom onset and those coming in between 4 to 12 hours. 
INCLUSION CRITERIA: 
1. All the patients with ischaemic symptoms admitted to the ICCU. 
EXCLUSION CRITERIA: 
1. Patients with Cerebrovascular accident. 
2. Patients with Renal diseases. 
3. Patients coming after 12 hours of symptom onset . 
Applying these criteria, 50 eligible patients were selected and included in 
the study after informed consent. 
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                                   METHODOLOGY 
A detailed history was taken and clinical examination was done in all 
the patients with particular reference to the cardiovascular system. Relevant 
urinary and blood investigations were done.ECG was taken in all the 
patients.CK-MB was measured. Qualitative estimation of Cardiac troponin I 
(cTnI) and Heart type fatty acid binding protein (H-FABP) was done using 
Cardiodetect qualitative immunological rapid test combi kit. 
Echocardiography  was done. Treatment given, complications and course in 
the hospital were recorded. Data collected was analysed statistically.  
 1. Socio-demographic data: 
Age                                  Sex                             Occupation    
    Family H/O hypertension, diabetes, IHD (Father/Mother/Siblings) 
H/O Alcohol, Smoking, Tobacco use, Diet history. 
2. Clinical data: 
A detailed clinical examination was done. Pulse, BP,JVP,  respiratory 
rate, temperature recorded. Pallor, icterus, cyanosis, clubbing, pedal 
oedema, lymphadenopathy were looked for.BMI was calculated.  
      BMI:108Body Mass Index(BMI) = Weight (kg) /( Height in metre) 2.  
Values         18.5 - 22.9 kg / m2 was taken as normal weight. 
                   23- 24.9 kg / m2 was taken as overweight. 
              ≥ 25 kg / m2 was taken as obesity. 
   General & Systemic examination done. 
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3. Laboratory data: 
Urine analysis: Urine sample was collected for urine routine analysis which 
included sugar, protein, cytology and urinary sediments.  
Blood sugar: Blood sugar was estimated by Trinder’s (Glucose oxidase) 
method and read at 505/670 nm.  
Renal function test: The blood urea was estimated using DAM method 
(Diacetyl Monoxime). Serum creatinine was estimated using Modified 
Jaffe’s method. Electrolytes were measured by absorption 
spectrophotometry. 
Lipid Profile: Total cholesterol and triglycerides measured using Trinder’s 
method. Total cholesterol <200mg/dl taken as normal and triglycerides 
<150mg/dl taken as normal.                         
ECG: Standard 12 lead ECG taken for all the patients. 
Echocardiography: Two dimensional Echocardiography was done for all 
the patients included in this study.                   
CK-MB: Estimated using Immunoinhibition method. Values <25 IU/L 
considered as normal. 
ESTIMATION  OF  TROPONIN I AND H-FABP : 
                         Estimation was done using Cardiodetect qualitative 
immunological rapid test combi kit. The test may be performed with 
capillary or venous whole blood, serum or plasma.The test field for both 
troponin I and H-FABP is filled with 3 to 4 drops of whole blood, serum or 
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plasma. The result is read after 15 minutes. If both the test (T) and control 
(C) lines are seen then it is taken as positive result. If only control (C) is 
seen then it is taken as negative result. If no line is seen then it is taken as 
invalid result. 
The test  principle:  
H-FABP: The test contains two different monoclonal antibodies 
specific for H-FABP, of which one is gold-labelled. The sample liquid 
releases the gold-labelled anti-FABP antibody from its matrix. This 
antibody forms an intermediary complex with the FABP present in the 
sample. This complex spreads across the test strip up to the position marked 
by ‘T’ where a second antibody is located. The intermediary complex and 
the second antibody form a sandwich complex showing up as a red line. A 
sample without H-FABP does not form a sandwich complex and therefore, 
forms no red line.  
 cTnI: If the sample contains cTnI , it interacts with anti cTnI 
antibodies and particles coated with the biotynilised anti cTnI antibodies. 
This complex passes over the test strip up to the position marked with ‘T’ 
where a line is coated with Streptavidin. The complex reacts with the 
Streptavidin showing up as a red line. A sample without cTnI forms no red 
line. 
 Integrated Function Control: The functioning of the test is indicated 
by the red control line at the position of the ‘C’ mark, because the excessive 
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gold-labelled antibodies gather here. The control line is formed if the 
sample has properly passed across the test field.This occurs irrespective of 
the concentration of the analyte in the sample. The test result is only valid if 
this line appears. 
Evaluation of the test: 
For H-FABP: 
 If 2 lines seen (at ‘C’ and ‘T’) - Positive (HFABP>7ng/ml). 
If only one line at ‘C’ - Negative (H-FABP<7ng/ml). 
No line or one line at ‘T’ only- Invalid test. 
For cTnI: :  
If 2 lines seen (at ‘C’ and ‘T’) - Positive (cTnI>1ng/ml). 
If only one line at ‘C’ - Negative (cTnI<1ng/ml). 
No line or one line at ‘T’ only- Invalid test. 
4. Statistical analysis: 
Data was entered in Microsoft excel spread sheet and analysed 
statistically using SPSS software version 17. 
Results were considered significant if the ‘p’ value was below 0.05. 
The following tests were used for statistical analysis: 
1. Chi – square test. 
2. Diagnostic Accuracy test 
3. Pearson’s correlation. 
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RESULTS 
 A total of 50 patients were selected. They were divided into two groups 
those presenting within 4 hours after the symptom onset and those 
presenting during 4-12 hours. 
 Out of 50 patients 22 presented within 4 hours (44%) and 28 patients 
presented during 4-12 hours (56%).There was no statistical difference 
between males and females with regard to time window of presentation 
to hospital after symptom onset.  
 39 patients were males (78%) and 11 were females (22%). 
 6 patients were aged <40 years (12%), 15 were in 40-50 years age 
group (30%), 17 in 50-60 years age group (34%) and 12 were aged >60 
years (12%). 
 Totally 22 patients (44%) had hypertension. Prevalence of 
hypertension was more among females (8 out of 11 i.e.72.7%) 
compared to males (14 out of 39 i.e. 35.9%).But there was no 
statistically significant difference between males and females with 
regard to diabetes mellitus. (10 among males and 5 among females). 
 Smoking and alcohol consumption were more common among the 
males. 34 males were smokers (87.2%), while only 2 females were 
smokers (18.2%).22 males used to consume alcohol (56.4%), while no 
females reported consuming alcohol.  
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 32 males and 6 females were positive for H-FABP (82.05% v/s 
54.55%).23 males and 5 females were positive for cTnI (59% v/s 
45.5%) while 16 males and 6 females had elevated CK-MB (41% v/s 
54.5%). This was statistically not significant.     
 Out of 22 patients presenting within 4 hours H-FABP was positive in 
16 patients (72.73%), cTnI was positive in 5 patients (22.73%) and 
CK-MB was positive in 2 patients (9.1%).The sensitivity was 60% for 
H-FABP, 18.8% for cTnI and 12.5% for CK-MB. The specificity was 
23.53% for H-FABP, 66.67% for cTnI and 100% for CK-MB.  
  Out of 28 patients presenting during 4-12 hours, H-FABP was positive 
in 22 patients (78.57%), cTnI was positive in 23 patients (82.1%) and 
CK-MB was positive in 20 patients (71.43%).The sensitivity was 
86.96% for H-FABP, 90.9% for cTnI and 77.3% for CK-MB. The 
specificity was 60% for H-FABP, 50% for cTnI and 50% for CK-MB. 
 Diagnostic accuracy of H-FABP was 31.82% within 4 hours and 
82.14% during 4-12 hours. Overall diagnostic accuracy compared to 
troponin was 60% and compared to CK-MB was 56%. 
 There was statistically significant correlation between ECG changes 
and Echocardiographic findings with H-FABP positivity (P value 
0.000). 
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 Number of death was 3 out of 38 patients who were positive for H-
FABP (7.9%) and nil among 12 patients who were negative for H-
FABP. All the 3 deaths were in females (3 out of 11= 27.27%) 
 The mean age group among H-FABP positive patients was 51.92 ± 
9.437 years and 55.92 ± 9.931 among H-FABP negative patients. 
 H-FABP was positive among 20 alcoholics (90.9%) and 18 
nonalcoholics (64.3%). This was statistically significant. But   H-FABP 
positivity did not show any statistically significant difference between 
smokers and non-smokers, hypertensives and normotensives, diabetics 
and normoglycaemics or those with elevated or normal BMI, 
triglycerides and cholesterol. 
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                                              TABLE- 1  
COMPARISON OF H-FABP WITH TROPONIN (0-4 HOURS) 
H-FABP 
TROPONIN 
TOTAL 
POSITIVE NEGATIVE
            POSITIVE 3(60%) 13(76.47%) 16(72.73%) 
            NEGATIVE 2(40%) 4(23.53%) 6(27.27%) 
            TOTAL 5(100%) 17(100%) 22(100%) 
Sensitivity = 60%                              Positive Predictive Value=18.75% 
Specificity= 23.53%                          Negative Predictive Value=66.67% 
Diagnostic Accuracy= 31.82% 
 
                                            TABLE-2 
COMPARISON OF H-FABP WITH CK-MB DURING 0-4 HOURS 
            H-FABP                CK-MB TOTAL 
POSITIVE NEGATIVE
POSITIVE 2(100%) 14(70%) 16(72.73%) 
            NEGATIVE 0 6(30%) 6(27.27%) 
            TOTAL 2(100%) 20(100%) 22(100%) 
Sensitivity = 100%          Specificity= 30%      
Positive Predictive Value=12.5%        Negative Predictive Value=100%  
Diagnostic Accuracy= 36.36% 
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TABLE-3 
  COMPARISON OF H-FABP WITH TROPONIN (4-12 HOURS) 
H-FABP 
TROPONIN TOTAL 
POSITIVE NEGATIVE
            POSITIVE 20(86.96%) 2(40%) 22(78.57%) 
            NEGATIVE 3(13.04%) 3(60%) 6(21.43%) 
            TOTAL 23(100%) 5(100%) 28(100%) 
Sensitivity = 86.96%                       Positive Predictive Value=90.91% 
Specificity= 60%                            Negative Predictive Value=50% 
Diagnostic Accuracy= 82.14% 
                                                 TABLE-4 
COMPARISON OF H-FABP WITH CK-MB DURING 4-12 HOURS 
H-FABP 
CK-MB 
TOTAL 
POSITIVE NEGATIVE
POSITIVE 17(85%) 5(62.5%) 22(78.57%) 
NEGATIVE 3(15%) 3(37.5%) 6(21.43%) 
TOTAL 20(100%) 8(100%) 28(100%) 
Sensitivity = 85          Specificity= 37.5%       
Diagnostic Accuracy= 71.43%   Negative Predictive Value=50% 
Positive Predictive Value=77.27%        
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TABLE-5 
OVERALL COMPARISON OF H-FABP WITH TROPONIN 
H-FABP 
TROPONIN 
TOTAL 
POSITIVE NEGATIVE
POSITIVE 23(82.14%) 15(68.18%) 38(76%) 
NEGATIVE 5(17.86%) 7(31.82%) 12(24%) 
TOTAL 28(100%) 22(100%) 50(100%) 
Sensitivity = 82.14%                           Positive Predictive Value=60.53% 
Specificity= 31.82%                            Negative Predictive Value=58.33% 
Diagnostic Accuracy= 60% 
                                            TABLE-6  
      OVERALL COMPARISON OF H-FABP WITH CK-MB 
H-FABP 
CK-MB 
TOTAL 
POSITIVE NEGATIVE
POSITIVE 19(86.36%) 19(67.86%) 38(76%) 
NEGATIVE 3(13.64%) 9(32.14%) 12(24%) 
TOTAL 22(100%) 28(100%) 28(100%) 
Sensitivity = 86.36%        Specificity= 32.14%     
 Diagnostic Accuracy= 56%  Negative Predictive Value=75% 
Positive Predictive Value=50%              
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TABLE-7 
         DISTRIBUTION OF H-FABP AMONG AGE GROUPS  
  AGE 
GROUP(YEARS) 
               H-FABP     TOTAL 
POSITIVE NEGATIVE 
<40 5(83.33%) 1(16.67%) 6(100%) 
40-50 11(73.33%) 4(26.67%) 15(100%) 
50-60 15(88.24%) 2(11.76%) 17(100%) 
>60 7(58.33%) 5(41.67%) 12(100%) 
TOTAL 38(76%) 12(24%) 50(100%) 
P Value is 0.298. statistically not significant. 
 There was no statistically significant difference in H-FABP positivity 
in various age groups. (P>0.05). 
TABLE-8 
DISTRIBUTION OF H-FABP AMONG MALES AND FEMALES 
      SEX       H-FABP TOTAL 
POSITIVE NEGATIVE
      MALE 32(82.05%) 7(17.95%) 39(100%) 
      FEMALE 6(54.55%) 5(45.45%) 11(100%) 
      TOTAL 38(76%) 12(24%) 50(100%) 
P value is 0.06. Statistically not significant.  
No statistically significant difference was noted between males and 
females with regard to H-FABP positivity. (P>0.05). 
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TABLE-9 
DISTRIBUTION OF H-FABP AMONG HYPERTENSIVES 
HYPERTENSION 
H-FABP 
TOTAL 
POSITIVE NEGATIVE
YES 17(77.27%) 5(22.73%) 22(100%) 
NO 21(75%) 7(25%) 28(100%) 
TOTAL 38(76%) 12(24%) 50(100%) 
P value is 0.852. Statistically not significant.  
 No statistically significant difference was noted between hypertensives  
And  normotensives with regard to H-FABP positivity. (P>0.05). 
                
TABLE-10 
DISTRIBUTION OF H-FABP AMONG DIABETICS 
DIABETES MELLITUS 
H-FABP 
TOTAL 
POSITIVE NEGATIVE
YES 9(60%) 6(40%) 15(100%) 
NO 29(82.86%) 6(17.14%) 35(100%) 
TOTAL 38(76%) 12(24%) 50(100%) 
    P value is 0.083. Statistically not significant. 
No statistically significant difference was noted between diabetics 
and normoglycaemic patients with regard to H-FABP positivity. (P>0.05). 
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TABLE-11 
DISTRIBUTION OF H-FABP AMONG SMOKERS 
SMOKING 
H-FABP 
TOTAL 
POSITIVE NEGATIVE
YES 30(83.33%) 6(16.67%) 36(100%) 
NO 8(57.14%) 6(42.86%) 14(100%) 
TOTAL 38(76%) 12(24%) 50(100%) 
P value is 0.052. Statistically not significant. 
 No statistically significant difference was noted between smokers 
and  Non-smokers with regard to H-FABP positivity. (P>0.05). 
TABLE-12 
DISTRIBUTION OF H-FABP AMONG ALCOHOLICS 
 
ALCOHOL    
CONSUMPTION 
H-FABP 
TOTAL 
POSITIVE NEGATIVE 
YES 20(90.90%) 2(9.10%) 22(100%) 
NO 18(64.30%) 10(35.71%) 28(100%) 
TOTAL 38(76%) 12(24%) 50(100%) 
P value is 0.029. Statistically significant. 
         There was statistically significant difference in H-FABP positivity 
between alcoholics and non alcoholics. (P<0.05). 
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TABLE-13 
DISTRIBUTION OF H-FABP AMONG  KILLIP CLASSES 
KILLIP CLASS 
H-FABP 
TOTAL 
POSITIVE NEGATIVE
I 23(79.31%) 6(20.69%) 29(100%) 
II 12(66.67%) 6(33.33%) 18(100%) 
III 2(100%) 0 2(100%) 
IV 19(100%) 0 1(100%) 
TOTAL 38(76%) 12(24%) 50(100%) 
P value is 0.576. Statistically not significant. 
There was no statistically significant difference in H-FABP positivity in 
patients of various Killip classes . (P>0.05). 
                                         TABLE-14 
   DISTRIBUTION OF H-FABP WITH REGARD TO BMI 
          BMI        H-FABP TOTAL 
POSITIVE NEGATIVE
      NORMAL 23(69.70%) 10(30.30) 33(100%) 
      INCREASED 15(88.24%) 2(11.76%) 17(100%) 
      TOTAL 38(76%) 12(24%) 50(100%) 
P value is 0.146. Statistically not significant. 
            No statistically significant difference was noted between patients  
with normal BMI and elevated BMI with regard to H-FABP positivity.  
(P>0.05).                  
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                                           TABLE-15 
            DISTRIBUTION OF H-FABP IN RELATION TO  
                                     TRIGLYCERIDES  
TRIGLYCERIDES 
H-FABP 
TOTAL 
POSITIVE NEGATIVE
NORMAL 7(64.64%) 4(36.36%) 11(100%) 
INCREASED 31(79.49%) 8(20.51%) 39(100%) 
TOTAL 38(76%) 12(24%) 50(100%) 
P value is 0.277. Statistically not significant. 
      No statistically significant difference was noted between patients with  
normal triglycerides and elevated triglycerides with regard to H-FABP  
positivity. (P>0.05).                                      
TABLE-16 
DISTRIBUTION OF H-FABP IN RELATION TO CHOLESTEROL 
CHOLESTEROL 
H-FABP 
TOTAL 
POSITIVE NEGATIVE
NORMAL 3(60%) 2(40%) 5(100%) 
INCREASED 35(77.78%) 10(22.22%) 45(100%) 
TOTAL 38(76%) 12(24%) 50(100%) 
P value is 0.377. Statistically not significant. 
No statistically significant difference was noted between patients with  
normal cholesterol and elevated cholesterol with regard to H-FABP  
positivity. (P>0.05).            
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TABLE-17 
DISTRIBUTION OF H-FABP IN RELATION TO  
ELECTROCARDIOGRAPH 
ECG 
H-FABP 
TOTAL 
POSITIVE NEGATIVE
ST ELEVATION 26(89.66%) 3(10.34%) 29(100%) 
OTHER CHANGES 12(85.71%) 2(14.29%) 14(100%) 
NO CHANGES 0 7(100%) 7(100%) 
TOTAL 38(76%) 12(24%) 50(100%) 
P value is 0.000. Statistically significant. 
Statistically significant difference was noted between those patients 
with  and without ECG changes with regard to H-FABP positivity. 
(P<0.05). 
TABLE-18 
DISTRIBUTION OF H-FABP IN RELATION TO 
ECHOCARDIOGRAPH 
ECHO 
H-FABP 
TOTAL 
POSITIVE NEGATIVE 
RWMA 32(91.43%) 3(8.57%) 35(100%) 
NO RWMA 6(40%) 9(60%) 15(100%) 
TOTAL 38(76%) 12(24%) 50(100%) 
P value is 0.000. Statistically significant. 
Statistically significant difference was noted between those patients  
with and without regional wall motion abnormality in echocardiograph  with 
regard to H-FABP positivity. (P<0.05). 
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TABLE-19 
DISTRIBUTION OF H-FABP IN RELATION TO 
THROMBOLYSIS 
THROMBOLYSIS 
H-FABP 
TOTAL 
POSITIVE NEGATIVE
      YES 25(89.29%) 3(10.71%) 28(100%) 
      NO 13(59.09%) 9(40.91%) 22(100%) 
      TOTAL 38(76%) 12(24%) 50(100% 
P value is 0.013. Statistically significant. 
             Statistically significant difference was noted between those  
patients who were thrombolysed and who were not thrombolysed, with  
regard to H-FABP positivity. (P<0.05). 
TABLE-20 
 DISTRIBUTION OF H-FABP IN RELATION TO DEATH 
      DEATH       H-FABP TOTAL 
POSITIVE NEGATIVE
      YES 3(100%) 0 3(100%) 
      NO 35(74.47%) 12(25.53%) 47(100%) 
      TOTAL 38(76%) 12(24%) 50(100%) 
P value is 0.315. Statistically not significant. 
   There was no statistically significant difference in H-FABP 
positivity  between those patients who died of MI and those who improved. 
(P> 0.05). 
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                                         DISCUSSION 
Acute myocardial infarction remains one of the most common causes 
of morbidity and mortality throughout the world and its incidence is 
increasing in developing countries including India 1.  
Early diagnosis and treatment is very important in preserving the 
myocardium and in limiting the ischaemic damage. Studies have shown that 
the serum levels of Gold standard cardiac biomarkers start to rise relatively 
late (3-4 hours in case of cardiac troponins and 4-6 hours in case of CK-
MB) and myoglobin which can be detected early is nonspecific to 
myocardium. Studies also have shown that nondiagnostic ECGs are 
recorded in approximately half of the patients presenting to emergency 
department with chest pain who ultimately are shown to have AMI. Hence 
an early biomarker is essential for the accurate diagnosis of AMI. Heart type 
fatty acid binding protein (H-FABP) has shown promise in this regard in 
various studies. 
This study compared the role of H-FABP in diagnosing AMI with 
that of cardiac troponin I and CK-MB. 
 In this study, in patients presenting within 4 hours of symptom onset, 
the sensitivity of H-FABP was 60% which was significantly higher than that 
of cTnI (18.8%) and CK-MB (12.5%).But specificity was only 23.53% in 
the initial 4 hours which was less than that of cTnI (66.67%) and CK-MB 
(100%). In patients presenting during 4 to 12 hours of symptom onset, the 
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sensitivity of H-FABP was 86.96% which was comparable to that of cTnI 
(90.9%) and CK-MB (77.3%).The specificity was 60% in the 4-12 hours 
group which was comparable to that of cTnI (50%) and CK-MB (50%). 
Diagnostic accuracy of H-FABP was 31.82% within 4 hours and 82.14% 
during 4-12 hours. Overall diagnostic accuracy compared to troponin was 
60% and compared to CK-MB was 56%. 
This observation is supported by some of the following studies. 
According to a study by Okamoto et al3 the overall sensitivity  within 
12 hours of symptom onset was 92.9% for H-FABP,88.6% for myoglobin 
and 18.6% for CK-MB. The overall specificity was 67.3% for H-FABP, 
57.1% for myoglobin and 98.0% for CK-MB. 
A study by Priya Gururajan et al102 at Chennai showed H-FABP to be 
a good discriminator between patients with and without IHD. It also showed 
that whereas troponin levels rise more than 6 hours after symptom onset, H-
FABP is usually positive within first 4 hours. At the optimum cut-off 
value(17.7 ng/ml) , the sensitivity and specificity were found to be 87% and 
93% respectively. 
A study by McCann CJ et al 109 showed, in patients presenting within 
4 hours of symptom onset, sensitivity of H-FABP higher than cTnT (73% 
v/s 53%). Specificity of H-FABP was 71%.Combined use of H-FABP and 
cTnT significantly improved the sensitivities of both to 85%. 
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In a study by Umut Cavus et al 110,H-FABP had a sensitivity equal to 
that of  CK-MB and superior to that of myoglobin (97.6% v/s 96.7% v/s 
85.4%) in initial 4 hours.H-FABP was more specific than CK-MB, 
myoglobin and Troponin T at the first hour (38.5%,34.6%,34.6%,23.1% 
respectively). 
In a study by Ecollan P et al 111, a positive H-FABP using 
cardiodetect assay had a significantly better sensitivity than cTnI, 
myoglobin and CK-MB (87.3% v/s 21.8%, 64.2% and 41.5% respectively). 
 A study by Ruzgar et al103 showed sensitivity of 38% with troponin, 
76% with CK-MB and 95% with H-FABP in patients admitted within 6 
hours of chest pain onset. 
A study by Seino Y et al 104 showed 89% sensitivity of H-FABP 
within 2 hours of symptom onset compared to 22% with troponin and 38% 
with myoglobin. 
In a  study by Mad P et al 105 , in 280 patients presenting to the 
hospital  with a median time of 3 hours of symptom onset, H-FABP had a 
sensitivity of 69% and specificity of 74% and AMI was diagnosed 
significantly earlier than by troponin. 
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LIMITATIONS OF THE STUDY: 
1. The sample size was small. 
2. Each patient was tested only once. Serial evaluation of the biomarkers 
was not done. 
3. Quantitative assay for troponin and H-FABP was not performed.  
4. Cardiac Troponin T and myoglobin not measured. 
5. This being a cross sectional study follow up was not done.  
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SUMMARY 
 The present study aimed at evaluating the role of heart type fatty 
acid binding protein in the diagnosis of acute myocardial infarction and also 
to compare it with the standard biomarkers troponin and  CK-MB. It also 
aimed at finding out the distribution of H-FABP with regard to variables 
like age and sex of the patient, BMI, lipid levels, smoking, alcoholism and 
in those with systemic hypertension and diabetes mellitus. It also aimed at 
correlating the H-FABP positivity with ECG and echocardiographic 
findings. With rigid criteria 50 patients were selected and enrolled in the 
study. 
 The H-FABP was found to be more sensitive but less specific 
compared to cardiac troponin I and CK-MB during the initial 4 hours of 
symptom onset. During the 4-12 hours of symptom onset the H-FABP 
showed similar sensitivity and specificity compared to cardiac troponin I 
and CK-MB. It did not show any significant difference between males and 
females, between  different age groups, between diabetics and non- 
diabetics, between hypertensives and normotensives, between smokers and 
non-smokers, between those having hyperlipidaemia and those having 
normolipidaemia.It showed significant difference between alcoholics and 
non-alcoholics but most probably it is an error due to small sample size. 
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                  This study recommends the selective and judicious use of heart 
type fatty acid binding protein along with the established biomarkers for the 
better diagnosis of Acute Myocardial Infarction. Further larger scale and 
follow up studies and further improvement in assay technique are required 
before it can be recommended as a single test.  
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CONCLUSION 
 
1. The heart type fatty acid binding protein is a sensitive biomarker for 
the diagnosis of acute myocardial infarction in the initial hours after 
symptom onset when the standard biomarkers may not be elevated. 
But it is less specific. 
 
2. During 4-12 hours of symptom onset it is as sensitive and specific as 
standard cardiac biomarkers troponin and CK-MB. 
 
 
3. The H-FABP assay is not influenced by the age, sex, BP, glycaemic 
status, BMI and lipid levels of the patient. 
 
4. Due to these factors H-FABP can be considered as a promising 
cardiac biomarker which can be used along with troponins and CK-
MB at present. With further larger scale studies and further 
improvement in the assay technique it can emerge as a cardiac 
biomarker which can be used alone, particularly in the early hours 
after symptom onset. 
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